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Background: In Mexico, diabetes mellitus is the main cause of end − stage kidney disease, and some patients may
be transplant candidates. Organ supply is limited because of cultural issues. And, there is a lack of standardized
clinical guidelines regarding organ donation. These issues highlight the tension surrounding the fact that living
donors are being selected despite being prediabetic. This article presents, examines and discusses using the
principles of non-maleficience, autonomy, justice and the constitutionally guaranteed right to health, the ethical
considerations that arise from considering a prediabetic person as a potential kidney donor.
Discussion: Diabetes is an absolute contraindication for donating a kidney. However, the transplant protocols most
frequently used in Mexico do not consider prediabetes as exclusion criteria. In prediabetic persons there are well
known metabolic alterations that may compromise the long − term outcomes of the transplant if such donors are
accepted. Even so, many of them are finally included because there are not enough donor candidates. Both,
families and hospitals face the need to rapidly accept prediabetic donors before the clinical conditions of the
recipient and the evolution of the disease exclude him/her as a transplant candidate; however, when using a
kidney potentially damaged by prediabetes, neither the donor’s nor the recipient’s long term health is usually
considered.
Considering the ethical implication as well as the clinical and epidemiological evidence, we conclude that
prediabetic persons are not suitable candidates for kidney donation. This recommendation should be taken into
consideration by Mexican health institutions who should rewrite their transplant protocols.
Summary: We argue that the decision to use a kidney from a living donor known to be pre-diabetic or from those
persons with family history of T2DM, obesity, hypertension, or renal failure, should be considered unethical in
Mexico if the donor bases the decision to donate on socially acceptable norms rather than informed consent as
understood in modern medicine.
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The population of Mexico is estimated to be 123,278,559
[1]. Type 2 diabetes mellitus (T2DM) affects 6.4 million
people [2], causing 40% of the cases of end-stage renal
disease (ESRD). This condition requires treatment with
dialysis (peritoneal or hemodialysis) or renal transplan-
tation. The Centro Nacional de Trasplantes, (CENATRA,
its acronym in Spanish, the agency responsible for the
national transplant system) reports that kidneys are the* Correspondence: aldo.nagisa@gmail.com
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distribution, and reproduction in any mediummost frequently requested organs in the country [3], while
the donation rate is low (5 donors per million inhabitants)
[4]. The most common form of renal transplantation in
patients with-ESDR secondary to T2DM is from living
donor (75% approximately), and the most common do-
nors are first degree relatives (i.e.: parents, brothers, etc.)
[5]. Donors therefore belong to the same risk population
as the organ receptor; and they are selected despite their
family history of T2DM or hypertension.
A person is diagnosed as prediabetic when she/he pre-
sents impaired fasting glucose (IFG) or impaired glucose
tolerance (IGT). The former is determined when fasting
blood glucose levels are between 100 mg/dl and 125 mg/dl.
The latter is determined when blood glucose levels areed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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tolerance test (OGTT) [6]. There is a controversy about
whether a pre-diabetic person may be considered as renal
donor candidate [7]. This controversy stems from three
fundamental facts: First, the prevailing notion that a pre-
diabetic person is “healthy”, which may not be entirely true.
According to the American Diabetes Association it is only
necessary to lose 7% of weight and do 150 minutes of
physical activity per week to control blood glucose levels
[8,9]. This goal is seemingly “easy” to achieve, yet it may
cause some physicians underestimate the potential risks of
prediabetes. Second, the lack of scientific publications ana-
lysing the long − term outcomes of prediabetic kidney do-
nors and the consequences of diminished renal tissue.
Third, the Amsterdam forum establishes that T2DM pa-
tients should not be renal donors because they have a high
risk of developing diabetic nephropathy; but it does not
make a statement about considering people with prediabe-
tes [10].
The overwhelming demand for kidneys exacerbates the
controversy; hence, most medical centres accept predia-
betic donors despite the risks in order to reduce the num-
ber of people on the waiting lists. This raises medical,
legal and ethical concerns: is reducing the number of
people on the waiting list all that matters? Due to known
donor prognosis, should we worry only about the welfare
of the organ recipient and not worry at all about the wel-
fare of the donor? What about the implementation of the
constitutionally guaranteed right to health?
This work intends to examine and discuss the ethical,
legal, and medical considerations about kidney donorTable 1 Studies linking glucose level with the development o
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CKF = Chronic Kidney Failure.selection in Mexico with the idea that such selection is
not only a technical −medical act that increases the
number of donors and decreases the number of people
in the waiting lists, but that also must be concerned
about the long − term prognosis of the donor and the re-
cipient and the ethics of such donations.
Discussion
Epidemiological evidence
The argument that prediabetes constitutes a risk factor for
T2DM
Prediabetes is not only associated with the development
of T2DM, it is possible that prediabetes, by itself, can in-
duce renal failure. This was observed in a crude analysis
of the data from 2,398 people in the Framingham Heart
Study (Table 1) which demonstrates that there is a 65%
risk of developing chronic kidney disease in persons with
IFG and IGT in comparison with normal persons [11].
In the case of a donor, this risk increases because of the
reduced renal mass [12].
A systematic review with data from 20 studies that in-
cluded an overall total of 95,783 people, with a median
of follow − up of 12.4 years (4–19 years), show that IFG
and IGT constitute a risk factor to cardiovascular events
(RR = 1.33 and 1.58 respectively) [16]. The same was ob-
served in the DECODE study (Diabetes Epidemiology:
Collaborative Analysis of Diagnostic Criteria in Europe)
where prediabetes increased mortality rate [17]. A meta-
analysis that included data from 10 randomized clinical
trials, and an overall total 23,152 people, shows that
treatment for IFG and IGT with diet, physical exercisef kidney damage
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stroke and decrease the frequency of myocardial infarc-
tion in comparison with control groups [18] thereby
showing that prediabetes poses an increase in risk for
these events.
Unilateral nephropathy increases 70% the glomerular
filtration rate and blood flow in the healthy kidney.
These changes, in the long − term, can end − up in renal
failure. This was demonstrated by Azar et al. (Table 1)
on a study where 55% of renal donors presented compli-
cations, 7% had an increase in creatinine levels and 10%
developed severe depression [15].
Moreover, the CARI guidelines (Caring for Australasians
with Renal Impairment), a set of periodically updated
guidelines strictly based on available evidence, included
the results from 11 studies in which renal donors −with-
out previously known risk factors −were monitored over
20 years [19]. The CARI guidelines report a global inci-
dence of T2DM ranking between 1.5% and 1.7%; and con-
clude that despite absence of prediabetes, kidney donors
could develop T2DM.
The argument that prediabetes does not constitute a risk
factor for T2DM
While previous studies demonstrate the importance of
excluding prediabetic persons as potential kidney donors,
other reports show a low incidence of T2DM among pre-
diabetic donors. This discussion recently re − emerged in
the ‘Kidney Week’, held in San Diego, California, in
December 2012. In the meeting of the American Society
of Nephrology held during that week, Chandran presented
the results from a retrospective cohort study performed
at the University of California, San Francisco, USA. He
monitored 35 renal donors with fasting glycemic levels
>109 mg/dl for a 10 − year period. He found that 31% of
the donors persisted with IFG, 11% developed T2DM, and
58% presented normal fasting glycemic levels [20]. These
results favour the notion that not all prediabetic indivi-
duals develop T2DM; hence, many doctors widen their
selection criteria of kidney donors based on these findings.
However, Chandran sets aside the remaining 42% of pre-
diabetic donors that continued to have impaired glucose
regulation, who could present nephropathy at long − term.
Chandran’s findings are consistent with the reported by
Faerch et al. who show that 30% of people with prediabe-
tes will not progress to T2DM [21]. A critical appraisal of
this statement should be done as in the Mexican popula-
tion exist conditions that increase the risk of such pro-
gression [22]; e.g.: family history of diabetes mellitus,
obesity, sedentary lifestyle, hypertension, gestational dia-
betes, and polycystic ovary syndrome in women.
As to the impact of nephrectomy, there are also some
publications that report that it is not associated with
impaired renal function or the development of othercomorbidities. For example, Narkun-Burgess et al. report
62 young men that underwent a nephrectomy secondary
to trauma during World War II. 28 out of 62 men died be-
fore 1993 and only six suffered changes in renal function
that were not related to the nephrectomy. In the survivor
group, five had macroproteinuria and three had serum
creatinine levels higher than 1.5 mg/dl. The authors
conclude that after a 45 − year follow − up; nephrectomy
did not contribute to renal failure nor increase mortality
among the subjects. It is important to highlight that
there are no prospective longitudinal studies that evalu-
ate the prognosis of prediabetic persons who undergo a
nephrectomy [23].
Therefore, the evidence is not conclusive. It seems that
the stronger epidemiological evidence shows that there
exists a high risk of developing T2DM in kidney donors
than the available evidence in favour of kidney trans-
plantation from living donors. But the uncertainty re-
mains. Nonetheless, the expected benefits for the renal
recipient along with the decrease in the number of
people waiting lists are tempting doctors to lean towards
renal transplantation. Which is the ethical decision?
The argument from a Mexican perspective
Most of the studies that explore the controversy in
authorizing or rejecting donation from prediabetic people
have been carried out among Caucasian populations.
Thus, in order to answer the ethical question it is neces-
sary to consider the fact that the Mexican population is
a Mestizo population, product of the intermarriage of
Caucasians and Native Americans, and as a result it
has significantly different genotypic and cultural charac-
teristics, and they have to be considered in the decision −
making process regarding organ donation in Mexico.
Genetically, Mexicans seem to be at higher risk for de-
veloping T2DM. Studies show that the population has
high frequencies of polymorphisms affecting some of the
genes involved in glucose and lipid metabolism. One of
them is the polymorphism on the HNF4A gene, which is
involved on insulin regulation and has a high frequency
among the Mexican mestizo population. Another poly-
morphism is the variant R230C from the ABCA1 gene,
one of the main risk alleles found on Amerindian or
Amerindian-derived populations [24]. Furthermore, 60%
of the Mexican population has a family history of diabetes.
This family background is associated with an increase in
fasting insulin levels (OR 1.7), a decrease in insulin sen-
sibility (OR 1.95), and an increase in the risk of diabetes
(OR 1.63) [25].
Regarding cultural characteristics, Mexico is a country
where the diet has been adversely modified recently by the
introduction of so − called “fast foods” and the increasing
consumption of sugar based beverages. Batis et al. found
that Mexicans’ dietary habits had become less healthy by
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diet between 1999 (low U.S. influence) and 2006 (high
U.S. influence) [26]. Likewise, Fanghälen-Salmón et al.
report that the prevalence of a sedentary lifestyle is of
almost 65 − 80% in the Mexican population [27]. And the
Mexican population does not easily accept the lifestyle
modifications that have to be made to treat prediabetes
[28]. Thus, it is expected that most of the Mexican predia-
betics will eventually become diabetic.
In order to detect chronic kidney disease among the
Mexican adult population, a pilot study was made by the
National Kidney Foundation: Kidney Early Evaluation
Program (KEEP). This study (performed in 2008) included
participants with T2DM and HTN with chronic kidney
disease. The survey required that the patients completed a
questionnaire and provided a blood and urine sample.
The results showed a high prevalence of chronic kidney
disease among participants with T2DM (38%), and with
T2DM and HTN (42%). It should be noted that most of
the participants ignored their health condition despite the
fact that 71% of them had visited their primary care phy-
sician in the previous year [29].
The legal argument: the unclear laws for organ donation
in Mexico
The Mexican General Law of Health [30] in Title 14, sec-
tion 333, establishes that the requirements for transplant-
ation from living donors are: to be older than 18 years of
age and in full possession of their mental faculties, to
donate organs with a function that can be compensated
by another organ, be compatible with the receptor, to re-
ceive complete information about the procedure before-
hand, to give informed consent and to have a family bond
with the receptor. The law does not consider any comor-
bidity as a restriction for donation.
Section 313 of the same law mentions that the Ministry
of Health is responsible for monitoring health issues du-
ring transplantation of organs, tissues, and cells of human
beings through the CENATRA. This agency establishes
that “medical and legal constraints will be analyzed in
each particular case by the internal transplant committee”
and that “to judge whether medical limitations exist,
health professionals must perform a detailed bioethical,
medical and legal assessment of the donor to eliminate
sanitary risk to the receptor, as well as to assure that the
organ and/or tissue be in acceptable condition to meet the
receptor’s needs”. It is noteworthy to mention that sec-
tions 326 and 332 of the same General Law of Health pro-
hibit the donation from minors (except for bone marrow),
the mentally incompetent, and pregnant women [30].
Again, the CENATRA’s guidelines do not specify the legal
aspects regarding comorbidities in the kidney donor.
The World Health Organization issued guidelines on
cell, tissue, and organ transplantation. Paragraph 10 statesthat: “High-quality, safe and efficacious procedures are
essential for donors and recipients alike. The long − term
outcomes of cell, tissue and organ donation and trans-
plantation should be assessed for the living donor as well
as the recipient in order to document benefit and harm.”
When the Mexican Law and the World Health Organi-
zation’s statement are compared it is obvious that the
Mexican laws and action plans are focused on the recep-
tor’s well − being. The Mexican law does not establish a
legal framework to identify donor comorbidities that
should contraindicate donation. In countries like Mexico,
with substantially high rates of T2DM, obesity, hyperten-
sion, and renal failure, and limited access to medical care,
the ethical issues regarding renal transplant require a
unique “national” approach in order to improve social and
moral regulations.
The argument from non −maleficience
Accepting a kidney from a Mexican living − donor with
prediabetes represents a risk for the donor, and it also
raises a question about whether the ethical principle of
primum non nocere (“first do no harm”) is being respected
[31]. The authors consider that sometimes the guidance
and authority of this ethical principle may be neglected
during the process of making the decision to transplant a
kidney from a prediabetic donor, especially when it is a
family member who needs the organ. It is necessary to
distinguish between donor well − being, and benefit to
others. Doctors have the moral obligation of exercising
due care, balancing intended benefits against risks and
inevitabilities of harm, physical, psychological, and social.
Primum non nocere, non-maleficience as it is now called,
should guide physicians to protect potential donors from
harming themselves, including prediabetics who “voluntarily”
decide to accept kidney donation for a family member or
others. If there is a possibility of injury to the donor, it might
be then considered that the recipient continues to be with
peritoneal dialysis or hemodialysis until a new donor without
comorbidities is located.
The argument from respect for person’s autonomy
It’s not easy to avoid the fact that society, health institu-
tions and family exert pressure for organ donation. For
potential donors, it is not easy to dispassionately consider
themselves as obligated donors. The decision to donate a
kidney to a family member, or friend, could be made
under a form of coercion that is socially accepted and yet
it denies the donor of the effective freedom to consent.
The potential donor may also be under the effect of an
undue influence to meet family values or the urgency of
the transplant team. However, respect for a person’s
autonomy and their right to freely consent or refuse an
intervention, are core values of modern medicine. The
autonomy of a person is respected when the risk and
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cussed before the potential donor makes a decision.
Although doctors cannot assure of each and every one of
the risks and benefits of donation, because each individual
is unique, transplant specialists must distinguish socially
acceptable decisions from ethical decisions. In Mexico,
a number of ethical questions immediately arise from
this question: can we talk about respect for autonomy
(the ability to take decisions freely without any coercion
or undue influence) when consent is given because it is
socially expected or when the risk and benefits of the
donation have not been fully explained?
Some health professionals believe that informed consent
releases them from the responsibility of protecting donors
because they “knowingly and voluntarily” accept the po-
tential damage to their health. This belief is in direct con-
flict with section four of the Mexican Constitution, which
states that every Mexican citizen has a right to health and
by implication a right to the decision that is in the best
interest of his/her health [32]. In fact, informed consent
must be a tool for donors and receptors to assess potential
risks and it must be designed to protect both of them
equally.
The argument that prediabetic living donor would be
incompatible with the ideal of justice
Justice requires treating people fairly, according to
their individual needs and merits [31]. A prediabetic has
high probabilities of develop T2DM and eventually renal
failure, thus, it is difficult to see that he/she needs or
merits to be considered for a kidney donation. Even so, it
could be difficult to see why renal transplantation from
prediabetic donor is inherently wrong, especially if the
person is fully aware of his/her own condition and its risks
and honestly believe that the donated kidney will improve
quality of life for a close relative or friend. It could be an
example of love. Such a potential donor is moved by care
and concern for the relative that will benefit from the do-
nation. The donor’s right to health is at issue. However, in
modern society there are many instances in which people
surrender their rights, even the right to life, in order to
benefit others. Such is the case of people in the Military
and in law enforcement. It may happen that a good pur-
pose is served; but the notion of human rights is a no-
tion that places limits on how an individual may be
treated, regardless of the good purposes that might be
accomplished.
Summary
There is an unmet demand for kidney for transplantation,
yet despite the obvious need, this is not sufficient justifica-
tion for the use of prediabetic living donors. Although epi-
demiologically there are arguments for and against, sound
prospective longitudinal studies that evaluate the prognosisof prediabetic persons are unavailable at the present time.
However, there are stronger epidemiological evidence and
typical aspects of the Mexican situation showing that there
exists a high risk of developing T2DM in prediabetic living
donor than the available evidence in favour of renal trans-
plantation. Ethical concerns emerge when donations from
prediabetic persons are analysed from the point of view of
the ethical principles of non −maleficience, autonomy and
justice. The doctors’ obligation to do no harm to their pa-
tients would seem imply that when conflict arises between
benefiting a patient that requires renal transplantation and
benefit a potential organ donor then prima facie the poten-
tial donor’s interests should take priority.
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